Cargando…

Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma

BACKGROUND: Reirradiation for locoregionally recurrent nasopharyngeal carcinoma (LR‐NPC) after high‐dose radiotherapy (RT) is challenging and usually is associated with poor survival and severe toxicities. Because of its physical and biological advantages over photon‐beam RT, carbon‐ion RT (CIRT) co...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiyi, Huang, Qingting, Gao, Jing, Guan, Xiyin, Hu, Weixu, Yang, Jing, Qiu, Xianxin, Chen, Mingyuan, Kong, Lin, Lu, Jiade J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693227/
https://www.ncbi.nlm.nih.gov/pubmed/32931035
http://dx.doi.org/10.1002/cncr.33197
_version_ 1783614695246135296
author Hu, Jiyi
Huang, Qingting
Gao, Jing
Guan, Xiyin
Hu, Weixu
Yang, Jing
Qiu, Xianxin
Chen, Mingyuan
Kong, Lin
Lu, Jiade J.
author_facet Hu, Jiyi
Huang, Qingting
Gao, Jing
Guan, Xiyin
Hu, Weixu
Yang, Jing
Qiu, Xianxin
Chen, Mingyuan
Kong, Lin
Lu, Jiade J.
author_sort Hu, Jiyi
collection PubMed
description BACKGROUND: Reirradiation for locoregionally recurrent nasopharyngeal carcinoma (LR‐NPC) after high‐dose radiotherapy (RT) is challenging and usually is associated with poor survival and severe toxicities. Because of its physical and biological advantages over photon‐beam RT, carbon‐ion RT (CIRT) could be a potential treatment option for patients with LR‐NPC. METHODS: Patients with LR‐NPC who underwent salvage therapy using CIRT at the Shanghai Proton and Heavy Ion Center between May 2015 and June 2019 were analyzed. CIRT doses were 50 to 69 gray equivalent (GyE) (2.0‐3.0 GyE per fraction). Overall survival (OS), local control, regional control, distant control, and acute and late toxicities were analyzed. Univariable and multivariable analyses of OS and local control were performed using the Cox regression model. RESULTS: Among the 206 patients included, 139 patients (67.5%) had recurrent American Joint Committee on Cancer stage III or stage IV disease. With a median follow‐up of 22.8 months, the 2‐year OS, local control, regional control, and distant control rates were 83.7%, 58.0%, 87.3%, and 94.7%, respectively. Multivariable analysis revealed that older age (P = .017) was predictive of worse OS, whereas a larger tumor volume (P = .049) and a lower biological equivalent dose (P = .029) were associated with inferior local control. No patient developed an acute toxicity of ≥grade 3 during CIRT. Severe (≥grade 3) late toxicities included temporal lobe necrosis (0.97%), cranial neuropathy (0.49%), hearing loss (1.46%), xerostomia (0.49%), and mucosal necrosis (16.02%) (toxicities were graded using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer criteria). CONCLUSIONS: Salvage treatment using CIRT is efficacious for patients with LR‐NPC and its toxicities are acceptable. CIRT may improve the survival and toxicity profiles substantially for patients with LR‐NPC compared with the reported results after photon‐based intensity‐modulated RT.
format Online
Article
Text
id pubmed-7693227
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-76932272020-12-11 Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma Hu, Jiyi Huang, Qingting Gao, Jing Guan, Xiyin Hu, Weixu Yang, Jing Qiu, Xianxin Chen, Mingyuan Kong, Lin Lu, Jiade J. Cancer Original Articles BACKGROUND: Reirradiation for locoregionally recurrent nasopharyngeal carcinoma (LR‐NPC) after high‐dose radiotherapy (RT) is challenging and usually is associated with poor survival and severe toxicities. Because of its physical and biological advantages over photon‐beam RT, carbon‐ion RT (CIRT) could be a potential treatment option for patients with LR‐NPC. METHODS: Patients with LR‐NPC who underwent salvage therapy using CIRT at the Shanghai Proton and Heavy Ion Center between May 2015 and June 2019 were analyzed. CIRT doses were 50 to 69 gray equivalent (GyE) (2.0‐3.0 GyE per fraction). Overall survival (OS), local control, regional control, distant control, and acute and late toxicities were analyzed. Univariable and multivariable analyses of OS and local control were performed using the Cox regression model. RESULTS: Among the 206 patients included, 139 patients (67.5%) had recurrent American Joint Committee on Cancer stage III or stage IV disease. With a median follow‐up of 22.8 months, the 2‐year OS, local control, regional control, and distant control rates were 83.7%, 58.0%, 87.3%, and 94.7%, respectively. Multivariable analysis revealed that older age (P = .017) was predictive of worse OS, whereas a larger tumor volume (P = .049) and a lower biological equivalent dose (P = .029) were associated with inferior local control. No patient developed an acute toxicity of ≥grade 3 during CIRT. Severe (≥grade 3) late toxicities included temporal lobe necrosis (0.97%), cranial neuropathy (0.49%), hearing loss (1.46%), xerostomia (0.49%), and mucosal necrosis (16.02%) (toxicities were graded using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer criteria). CONCLUSIONS: Salvage treatment using CIRT is efficacious for patients with LR‐NPC and its toxicities are acceptable. CIRT may improve the survival and toxicity profiles substantially for patients with LR‐NPC compared with the reported results after photon‐based intensity‐modulated RT. John Wiley and Sons Inc. 2020-09-15 2020-12-01 /pmc/articles/PMC7693227/ /pubmed/32931035 http://dx.doi.org/10.1002/cncr.33197 Text en © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Hu, Jiyi
Huang, Qingting
Gao, Jing
Guan, Xiyin
Hu, Weixu
Yang, Jing
Qiu, Xianxin
Chen, Mingyuan
Kong, Lin
Lu, Jiade J.
Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
title Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
title_full Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
title_fullStr Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
title_full_unstemmed Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
title_short Clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
title_sort clinical outcomes of carbon‐ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693227/
https://www.ncbi.nlm.nih.gov/pubmed/32931035
http://dx.doi.org/10.1002/cncr.33197
work_keys_str_mv AT hujiyi clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT huangqingting clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT gaojing clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT guanxiyin clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT huweixu clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT yangjing clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT qiuxianxin clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT chenmingyuan clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT konglin clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma
AT lujiadej clinicaloutcomesofcarbonionradiotherapyforpatientswithlocoregionallyrecurrentnasopharyngealcarcinoma